Pfizer ends Alzheimer research: an emergency signal for medicine and politics

Pfizer, the worlds greatest pharmaceutical company (business volume 2016 52,8 billion US$) has ended its efforts in Alzheimer - research. The decision was conclusive: There is no realistic assumption that the invested money can be recov􏰀 ered. The decision was driven by science, not by costs or a lack of qualified scientists: The currently used scientific views from our world (paradigms) are not adequate for the needed scientific challenge. The relevance of Alzheimer for the world wide level of health - and therefore for the cost of related drugs - will increase dramatically because of the shift in the age distribution. So the level of health will decrease. Both facts should be warning signals for decision makers for the future of medicine and politics to reassess the actually used strategies. There is hope if one were able to undertake the following two steps: first to develop a more appropriate paradigmatic model and second to transfer it into specific applicable tools. The «Extended View» is such a paradigmatic model. The model is a matter of further development within IAS􏰀HE and Sechenov University. It is matter of interdisciplinary discussions e.g. within the Russian Academy of Science. Principles of the model are presented.